ArticleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2026
A decision-making process to guide the potential application of a hepatitis A virus and parvovirus B19 nucleic acid test for qualifying plasma for fractionation.
Article in Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Roche cobas DPX assay (Roche Diagnostics) is a nucleic acid test (NAT) that detects parvovirus B19 (B19V) and hepatitis A virus (HAV) and enhances the safety of fractionated plasma protein products. Implementation of this NAT requires multiple decisions focused on test characteristics, test operationalization, and result interpretation. This study uses a decision-making process to guide the potential application of this NAT to qualify plasma for fractionation. Methods: A basic decision tree approach was used to undertake a stepwise feasibility study of the B19V/HAV assay in a blood donor setting. Limit of detection, reproducibility, and pooling studies utilized mocked-up B19V (genotypes 1 and 2) and HAV (genotypes 1a, 2a, and 3a) specimens (BioQControl; Biologicals Quality Control B.V.), Somagen (LGC SERACARE), and anonymized COVID-19 convalescent plasma (CCP; Canadian Blood Services). The Hamilton Microlab STAR IVD Pipettor generated HAV and B19V specimen pools of 96, 24, and 6. Pools and individual specimens were tested using the DPX (Duplex HAV and Parvovirus B19 Nucleic Acid Test) on the cobas 6800/8800 System. Data were collated using Excel (Microsoft, Seattle, WA, USA). Results: The Roche cobas DPX reproducibly detected dilutions of B19V and HAV. Pools of 24 and 6 reproducibly detected B19V at acceptable Ct values; pools of 6 reproducibly detected HAV, although at later Ct values. Conclusions: Using a simple decision tree approach, this study describes how a B19V and HAV NAT could be applied for the qualification of plasma for fractionation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.